BlossomHill Therapeutics, Inc.(BLSM)

Biotechnology · San Diego, CA

$18.41-1.53 (-7.67%)

Delayed quote: Oct 6, 2026, 1:10 PM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T17:11:10.680Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:11:10.680Z.

Quote observation: 2026-10-06T17:10:11.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 535,384,156
TTM operating cash flow · period ending 2026-06-30: N/A

FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BLSM Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

BLSM Competitors' Price/OCF Ratio

BLSM

BlossomHill Therapeutics, Inc.

Current

Market Cap

$535.38M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STTK

Shattuck Labs, Inc.

vs BLSM

Market Cap

$543.14M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NVCT

Nuvectis Pharma, Inc.

vs BLSM

Market Cap

$537.90M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACRS

Aclaris Therapeutics, Inc.

vs BLSM

Market Cap

$541.90M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCTH

Delcath Systems, Inc.

vs BLSM

Market Cap

$536.12M

Price/OCF Ratio

27.37

TTM Avg

30.64

3Y Avg

39.07

5Y Avg

39.07

PROK

ProKidney Corp.

vs BLSM

Market Cap

$536.32M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PHAT

Phathom Pharmaceuticals, Inc.

vs BLSM

Market Cap

$535.11M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMMX

Immix Biopharma, Inc.

vs BLSM

Market Cap

$524.71M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MNPR

Monopar Therapeutics Inc.

vs BLSM

Market Cap

$523.83M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MMEDV

MiniMed Group, Inc.

vs BLSM

Market Cap

$560.00M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
BlossomHill Therapeutics, Inc. (BLSM)	$535.38M	N/A	N/A	N/A	N/A
Shattuck Labs, Inc. (STTK)vs ›	$543.14M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$537.90M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$541.90M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$536.12M	27.37	30.64	39.07	39.07
ProKidney Corp. (PROK)vs ›	$536.32M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$535.11M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$524.71M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$523.83M	N/A	N/A	N/A	N/A
MiniMed Group, Inc. (MMEDV)vs ›	$560.00M	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

BLSM Price/OCF Ratio Metrics

BLSM Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics